New York-based cancer specialist Bristol Myers Squibb (NYSE: BMY) has picked up a new US Food and Drug Administration approval for its checkpoint blocker Opdivo (nivolumab).
The label update covers use of the therapy, in combination with platinum-doublet chemotherapy, to treat non-small cell lung cancer (NSCLC) in the neoadjuvant setting.
The approval is based on the CheckMate -816 trial, which met primary endpoints of event-free survival (EFS) and pathologic complete response (pCR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze